2012-02-13 10:30:11 -

co.don AG /
co.don AG: positive business performance in 2011
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

Brandenburg-based  biotech  company  increases  revenue despite difficult market
conditions

co.don  AG,  one  of  the  leading  companies  in  the  production of autologous
cartilage  cell transplants for articular and vertebral damage, can look back on
a  successful financial year 2011. On the  basis of preliminary figures, revenue
in  Germany rose by  around 28% (unaudited). Allowing  for lost sales in foreign
markets, especially Italy and Greece, due to the economic climate, total revenue
growth  of around 8% to EUR 2.3m (unaudited) was achieved in   2011. Product sales
volumes  also rose  sharply by  a total  of around  11% (unaudited), whereby the
sales increase in Germany was in excess of 26%.

Due  to very substantial investment in two clinical trials, co.don AG will close
2011 with  a  negative  operating  result.  This  investment is justified by the
market  authorisation for the whole EU that  a successful trial would bring. The
patented  procedure,  which  qualifies  for  reimbursement by health insurers in
Germany,  has already been  applied successfully thousands  of times in Germany.
"Access   to  30 European  countries  will  lead  to  a  completely  new  market
positioning  and a  massive increase  in the  potential market", explains CEO Dr
Andreas Baltrusch.

The fact that the trials are proceeding quickly and efficiently formed the basis
for the capital increase adopted by the Executive Board and Supervisory Board of
co.don AG in January 2011 and implemented in May 2011.

A  simplified capital reduction and  a 2:1 reverse share split  was voted at the
ordinary  shareholders' meeting  of co.don  AG held  on 6 July  2011. The equity
transaction reduced share capital to EUR 7,108,584.00. The capital reduction was
entered  in  the  commercial  register  on  26 August 2011 and serves to prepare
further equity transactions.

In  mid 2011, co.don and its sales partner  ORMED (now DJO GLOBAL), were able to
sign  a  supply  contract  with  Asklepios  Group,  Germany's  largest  hospital
operator.   This will enable  patients with articular  cartilage problems at the
Asklepios   Clinics  throughout  Germany  to  be  treated  with  the  cell-based
biological drug ARTROCELL 3D(®) / co.don chondrosphere(®).

In  November 2011 co.don AG  was also awarded  the Entrepreneurship Prize by the
East  German Savings Bank Association. The prize is one of the most sought-after
awards  in  Eastern  Germany  and  honours  the  performance and entrepreneurial
commitment  of the innovative, Teltow-based  biotech specialist for regenerative
medicine.

"Over  4,000 patients have already received  articular and spinal disc treatment
and  the success  ratio is  very high",  said Dr  Baltrusch. Public and private-
sector  health  insurers  already  reimburse  the  costs  of treatment with this
method, which is much easier on the patient than other therapeutic options. More
than  175,000 knee replacements are carried out every year in Germany - a figure
which according to Baltrusch is much too high. "With our procedure", says co.don
CEO, "knees can be repaired gently and replacement surgery often averted."

About co.don(®) AG:
The  company is  based in  Teltow, Brandenburg,  and was  founded in 1993. Since
2001 the  bio-pharmaceutical specialist has  been listed on  the Frankfurt Stock
Exchange   (ISIN:  DE000A1K0227).  co.don  AG  uses  tissue  engineering  -  the
cultivation  and  growth  of  autologous  tissue  cells  - to develop innovative
products and therapeutic concepts for the orthopaedic and neurosurgical markets.
The  cell-based  biological  drugs  (autologous  cell  transplants for articular
cartilage and intervertebral disks) are produced without the use of antibiotics,
growth  factors and genetic  engineering. The Management  Board of co.don® AG is
made up of Dr Andreas Baltrusch (CEO) and Ms Vilma Siodla (COO).
Further information is available from:www.codon.de

Press contact
BrunoMedia Communication GmbH
Gerd J. Gauger
Bonner Straße 328
50968 Cologne
 Tel:     0221-348 038 10

 Fax:     0221-348 038 70

 Email:   codon@brunomedia.de






Press release (PDF) : 
 hugin.info/132731/R/1584921/496004.pdf




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: co.don AG via Thomson Reuters ONE

[HUG#1584921]